141 related articles for article (PubMed ID: 12434690)
1. Enhanced surveillance scheme for suspected meningococcal disease in five regional health authorities in England: 1998.
Davison KL; Crowcroft NS; Ramsay ME; Begg NT; Kaczmarski EB; Stuart JM; White JM; Orr H;
Commun Dis Public Health; 2002 Sep; 5(3):205-12. PubMed ID: 12434690
[TBL] [Abstract][Full Text] [Related]
2. National enhanced surveillance of meningococcal disease in England, Wales and Northern Ireland, January 1999-June 2001.
Shigematsu M; Davison KL; Charlett A; Crowcroft NS
Epidemiol Infect; 2002 Dec; 129(3):459-70. PubMed ID: 12558328
[TBL] [Abstract][Full Text] [Related]
3. Estimating the burden of serogroup C meningococcal disease in England and Wales.
Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
[TBL] [Abstract][Full Text] [Related]
4. Investigating the aetiology of and evaluating the impact of the Men C vaccination programme on probable meningococcal disease in England and Wales.
Granerod J; Davison KL; Ramsay ME; Crowcroft NS
Epidemiol Infect; 2006 Oct; 134(5):1037-46. PubMed ID: 16492318
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
Trotter CL; Ramsay ME; Kaczmarski EB
Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of invasive meningococcal disease in Queensland, 2002.
Pugh RE; Smith H; Young M
Commun Dis Intell Q Rep; 2003; 27(3):342-51. PubMed ID: 14510059
[TBL] [Abstract][Full Text] [Related]
7. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005.
Can Commun Dis Rep; 2007 Jun; 33(10):1-15. PubMed ID: 17691125
[No Abstract] [Full Text] [Related]
8. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales.
Ramsay M; Kaczmarski E; Rush M; Mallard R; Farrington P; White J
Commun Dis Rep CDR Rev; 1997 Apr; 7(4):R49-54. PubMed ID: 9127510
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
[TBL] [Abstract][Full Text] [Related]
11. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003.
Can Commun Dis Rep; 2006 Apr; 32(8):97-107. PubMed ID: 16685767
[No Abstract] [Full Text] [Related]
12. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
De Wals P; Deceuninck G; Boulianne N; De Serres G
JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
[TBL] [Abstract][Full Text] [Related]
13. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
Ramsay ME; Andrews NJ; Trotter CL; Kaczmarski EB; Miller E
BMJ; 2003 Feb; 326(7385):365-6. PubMed ID: 12586669
[No Abstract] [Full Text] [Related]
14. Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China.
Ni JD; Jin YH; Dai B; Wang XP; Liu DQ; Chen X; Zheng Y; Ye DQ
Postgrad Med J; 2008 Feb; 84(988):87-92. PubMed ID: 18322129
[TBL] [Abstract][Full Text] [Related]
15. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
Mooney JD; Christie P; Robertson C; Clarke SC
Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
[TBL] [Abstract][Full Text] [Related]
16. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
[TBL] [Abstract][Full Text] [Related]
17. Changes in Meningococcal Strains in the Era of a Serogroup C Vaccination Campaign: Trends and Evolution in Belgium during the Period 1997-2012.
Mattheus W; Hanquet G; Collard JM; Vanhoof R; Bertrand S
PLoS One; 2015; 10(10):e0139615. PubMed ID: 26425857
[TBL] [Abstract][Full Text] [Related]
18. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
[TBL] [Abstract][Full Text] [Related]
20. Annual report of the Australian Meningococcal Surveillance Programme, 2007.
Tapsall J;
Commun Dis Intell Q Rep; 2008 Sep; 32(3):299-307. PubMed ID: 19062765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
